Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to ...

The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa ...

Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for ...

A report from DelveInsight highlights over 20 companies developing 22 treatments for myotonic dystrophy, with progress in ...

The US Food and Drug Administration (FDA) yesterday announced its Fiscal Year 2025 Generic Drug User Fee Amendments (GDUFA).

The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of ...

Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

UK-based drugmaker Advanz Pharma has announced that following the grant of a temporary suspension, as announced on last month ...